Lindahl advises Corline Biomedical AB on directed share issue
Lindahl is acting as legal adviser to Corline Biomedical AB (publ) in connection with a directed share issue amounting to approximately SEK 23 million.
Through the share issue, Corline Biomedical will receive approximately SEK 23 million before deduction of issue costs. In addition, the company strengthens its shareholder base with a long-term and international investor, Eiffel Investment Group, to which the issue is directed.
Corline Biomedical develops and sells medical technology solutions. The company's shares are listed on Nasdaq First North Growth Market.
Lindahl's team consists of Mattias Prage and Olle Swärd Brattström.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatOlle Swärd Brattström
AssociateCarousel items
-
News articles
4/1/2026
Insights from Oxford: climate transition is business-critical
When leading experts gathered in Oxford for this year's Climate Policy Monitor symposium, one thing was clear: climate is no longer purely a regulatory issue – it is business-critical.
-
Knowledge
3/30/2026
How to deal with bankruptcy during legal proceedings
What happens to ongoing legal proceedings if the opposing party goes bankrupt? We explain the estate's right to take over the claim and the risks involved.
-
Cases and transactions
3/23/2026
Lindahl advises Seafire on the acquisition of Splendor Plant AB
Lindahl has acted as legal adviser to Seafire in connection with the acquisition of all shares in Splendor Plant AB, the Nordic region's leading wholesale plant nursery, and in negotiations regarding an expanded financing agreement with its existi...
-
Portraits
1/20/2026
How I use AI in my daily work as a lawyer
AI is no longer the future – it is everyday reality. Johanna Karlsson, lawyer and senior associate at Lindahl, talks about how AI tools such as Legora have become a natural part of her workflow.
-
Read more news and insights?
